MedWatch

Novo Holdings has worked large Convatec investment for four years: "Things don't happen overnight"

Having been a large stakeholder in UK company Convatec for almost four years, Novo Holdings has yet to gain success from this investment. CEO Kasim Kutay stays optimistic.

Novo Holdings CEO Kasim Kutay | Photo: Novo Holdings / PR

The wealthy holding company Novo Holdings has burnt its fingers investing billions of kroner in medtech company Convatec.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs